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Abstract
Persistent TH2 cytokine responses following chronic helminth infections can often lead to
the development of tissue pathology and fibrotic scarring. Despite a good understanding of
the cellular mechanisms involved in fibrogenesis, there are very few therapeutic options
available, highlighting a significant medical need and gap in our understanding of the molec-
ular mechanisms of TH2-mediated immunopathology. In this study, we found that the Map3
kinase, TPL-2 (Map3k8; Cot) regulated TH2-mediated intestinal, hepatic and pulmonary
immunopathology following Schistosoma mansoni infection or S.mansoni egg injection.
Elevated inflammation, TH2 cell responses and exacerbated fibrosis inMap3k8
–/–mice was
observed in mice with myeloid cell-specific (LysM) deletion ofMap3k8, but not CD4 cell-
specific deletion ofMap3k8, indicating that TPL-2 regulated myeloid cell function to limit
TH2-mediated immunopathology. Transcriptional and metabolic assays ofMap3k8
–/–M2
macrophages identified that TPL-2 was required for lipolysis, M2 macrophage activation
and the expression of a variety of genes involved in immuno-regulatory and pro-fibrotic
pathways. Taken together this study identified that TPL-2 regulated TH2-mediated inflam-
mation by supporting lipolysis and M2 macrophage activation, preventing TH2 cell expan-
sion and downstream immunopathology and fibrosis.
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Author Summary
Chronic helminth infections can cause significant morbidity and organ damage in their
definitive mammalian hosts. Managing this collateral damage can reduce morbidity and
preserve vital tissues for normal organ function. One particular consequence of some
chronic helminth infections is the deposition of fibrotic scar tissue, following immune
responses directed towards helminth material. In this study we tested the role of a particu-
lar signalling kinase, TPL-2, and identified that it critically regulated the magnitude of
fibrotic scarring following infection. Using several murine models with genetic deletions
of TPL-2 in either all cells or specific deletion in subsets of immune cells (Map3k8–/
–Map3k8fl/fl) we identified that expression of TPL-2 in myeloid cells was essential to pre-
vent severe immune-mediated pathology. Using genome-wide analyses and metabolic
assays, we discovered that TPL-2 was required for normal lipid metabolism and appropri-
ate activation of myeloid cells / macrophages to limit fibrosis. These results revealed a pre-
viously unappreciated role for TPL-2 in preventing severe pathology following infection.
Thus, activating this pathway may limit immune mediated pathology following chronic
helminth infection. More broadly, this pathway is being targeted to treat inflammatory
diseases and cancer [1, 2]. This study would suggest that caution should be taken to pre-
vent untoward co-morbidities and fibrosis-related pathologies in patients when targeting
TPL-2.
Introduction
Immune-mediated pathologies and fibrotic scarring are a major cause of global morbidity and
mortality. This is due, in part, to a shortage of available drugs and a lack of novel therapeutic
targets to limit fibrogenesis, highlighting a major unmet medical need [3, 4]. Chronic infection
resulting in recurring inflammation and wound repair can lead to tissue remodelling, fibrosis
and ultimately organ failure. Infection with the parasitic blood fluke, Schistosoma mansoni, can
cause severe intestinal and hepatic pathologies caused by fibrotic lesions surrounding trapped
parasite material. Parasite eggs become lodged within vascularised tissue invoking a distinctive
eosinophil and macrophage (MF)-rich type-2 immune-mediated granuloma [5]. TH2-cell
derived IL-4 and IL-13 [6] stimulate IL-4 receptor (IL-4R)-expressing MF’s [7, 8] to develop
an M2 or alternative activation (AA) state characterised by expression of Arginase (Arg1),
Resistin-like molecule alpha (Retnla, Fizz-1) and chitinase-like molecules (Chi3l3, Chi3l4) [9].
Animal models have indicated that IL-4R-dependent M2-MF’s are essential to 1) prevent fatal
intestinal damage and sepsis following schistosome infection [7]; 2) orchestrate tissue remodel-
ling and fibrotic responses [10–12] and 3) regulate TH2 cell proliferation and activation [13–
15]. Despite the clear and well-documented importance of M2-MF’s during schistosome infec-
tion and the resulting immune-mediated protection, pathology and regulation, the critical reg-
ulatory proteins that control M2-MF differentiation are poorly understood.
The MAP3 kinase, TPL-2 (also known as COT and encoded byMap3k8) is ubiquitously
expressed, phosphorylating and activating MEK1/2 following stimulation of Toll-like receptors
(TLRs) and the receptors for TNF and IL-1β, leading to the activation of ERK1/2 MAP kinases
[16]. TPL-2 is required for TH1 and TH17-associated inflammation and is essential for the
development of autoimmunity and immunity to bacterial and protozoan pathogens [17–20].
In MF’s, TPL-2 is required for the synthesis and secretion of a variety of cytokines and chemo-
kine’s following classical activation (CA) with TLR ligands [17, 20–29]. However, it is unclear
TPL-2 Regulates Fibrosis
PLOS Pathogens | DOI:10.1371/journal.ppat.1005783 August 3, 2016 2 / 26
whether TPL-2 controls M2-MF function to regulate chronic TH2-associated inflammation
and immunopathology.
Two distinct inflammatory pathways contribute to fibrogenic responses; classical, pro-
inflammatory type-1/17 and TGF-β-mediated fibrosis [30] and type-2 inflammatory pathways
leading to IL-4R-dependent fibrosis [4]. It was recently reported that TPL-2–deficient mice, or
inhibition of ERK [31], protected mice from type-1/TH17 and TGFβ-mediated pulmonary
fibrosis following bleomycin treatment [31] and from hepatic fibrosis following carbon tetra-
chloride and methionine choline-deficient diet-induced fibrosis [32]. As expected,Map3k8–
deficient Kupffer cells had reduced TLR-induced IL-1β and pro-fibrotic gene expression,
which the authors suggested was responsible for the reduced hepatic fibrosis in vivo. However
this was not directly tested. Nevertheless, this study raised the possibility that targeting TPL-2
may forestall the progression of hepatic fibrosis. Indeed many small molecule inhibitors have
been developed that block TPL-2 signalling in vitro [2], but none have yet made it in to the
clinic. However, it is not known whether TPL-2 contributes to chronic type-2 inflammation
and IL-4R-mediated fibrosis.
In this study, we used the well-established Schistosoma mansoni infection model to test
whether TPL-2 regulated chronic type-2 associated inflammation, immunopathology and
fibrosis. In contrast to the reduced fibrosis observed inMap3k8–/–mice following chemical and
diet-induced fibrosis [32],Map3k8–/–mice had significantly increased type-2 immune
responses with concomitant elevated inflammation and fibrosis surrounding trapped parasite
eggs. Using genome-wide transcriptional analysis and metabolic assays we found that TPL-2
was required for lipid oxidative metabolism and M2-MF activation. Specifically, TPL-2 was
required for expression of immunoregulatory molecules (Retnla and Arg1) and regulated pro-
fibrotic genes (Col genes and Ctgf). Consequently, myeloid cell-specific deletion ofMap3k8
resulted in increased type-2 inflammation and significantly increased fibrosis in vivo, phenoco-
pyingMap3k8–/–mice. Collectively, our study identifies a novel and previously unappreciated
role for TPL-2 as a molecular regulator of lipolysis in M2-MF’s, regulating type-2 inflamma-
tion, immunopathology and hepatic fibrosis.
Results
Map3k8-deficient mice develop increased TH2-mediated
immunopathology and fibrosis following infection with Schistosoma
mansoni
Following maturation and worm pairing, gravid worms release hundreds of eggs, many of
which traverse the wall of the intestine and are released into the environment via the fecal
route. However, many eggs do not successfully reach the intestinal lumen but instead become
trapped in the intestinal wall or within vascularised organs, particularly the liver. An eosinophil
and MF-rich fibrotic granuloma forms around trapped eggs causing significant tissue damage,
orchestrated by CD4+ TH2 cells and a highly polarised type-2 immune response [5].
To test whether TPL-2 contributed to S.mansoni-associated intestinal and hepatic pathol-
ogy and fibrosis, we infectedMap3k8–/–mice with 50 S.mansoni cercariae.
Histological analysis indicated that S.mansoni-infectedMap3k8–/–mice had more fibrosis in
the liver with larger hepatic granulomas (Fig 1A and 1B), despite a similar egg burden (S1 Fig)
and serum LPS level as S.mansoni-infectedWTmice (S1 Fig). Similarly, intestinal inflammation
was also significantly increased inMap3k8–/–mice (Fig 1C and 1D). Consistent with the increased
collagen staining observed inMap3k8–/–mice, collagen-synthesising genes, Col3 and Col6, were
both significantly elevated in the liver and small intestine ofMap3k8–/–mice, compared to WT
controls (Fig 1E), with significantly more hydroxyproline in the liver ofMap3k8–/–mice (Fig 1F).
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Fig 1. Map3k8–/–mice develop increased hepatic and intestinal inflammation and fibrosis following S.mansoni
infection.WT andMap3k8–/–mice were infected percutenously with 50 S.mansoni cercariae and analysed at 8 weeks
post-infection. A & C) Perfused tissue was fixed and embedded in paraffin before sectioning and staining with Masson’s
trichrome. B) Granuloma size was determined from 10–20 individual granulomas per sample measured using Image J.
Scale bars are 1000μm (top), 200μm (middle) and 100μm (bottom). D) Intestinal pathology score, as described in
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Map3k8–/–mice had elevated expression of Il13 in the liver, but not Il1b, Tgfb, Il17a, Ifng, Tnfa or
Il6 (S1 Fig), suggesting that IL-13-driven fibrosis was exacerbated inMap3k8–/–mice [33] rather
the development of other inflammatory mechanisms of fibrosis [30].
CD4+ TH2 cell-derived IL-4 and IL-13 are essential for granuloma formation [6], mobilising
and activating a suite of innate immune cells, including MF’s and eosinophils, and promoting
local collagen deposition. TH2 cell-mediated inflammatory responses are controlled by Foxp3
+
regulatory T (TREG) cells [34], which restrain TH2 cell expansion. It was previously suggested
that T cell intrinsic TPL-2 regulates TH2 [35] and Foxp3
+ TREG cell differentiation [36]. How-
ever, these conclusions were based on in vitro experiments and were not tested in vivo. To deter-
mine whetherMap3k8–/–mice had dysregulated TH2 and Foxp3
+ TREG responses following S.
mansoni infection, we crossedMap3k8–/–mice with Il4gfp and Foxp3rfp reporter mice, generating
dual-reporterMap3k8–/–mice (Map3k8–/–Foxp3rfpIl4gfp). These reporter mice allowed us to
accurately and simultaneously monitor TH2 (Il4
gfp+) and Foxp3+ TREG (Foxp3
rfp+) cells in
Map3k8–/–mice without the requirement for re-stimulation or intra-nuclear staining.Map3k8-
deficiency did not alter CD4+CD25+Foxp3rfp+ TREG cell frequencies in the spleen, mesenteric
lymph node (MLN) or in the local liver tissue, indicating that TPL-2 was not required for TREG
cell development or recruitment following S.mansoni infection (Fig 1G, top row). However,
CD4+CD44+Il4gfp+ TH2 cells in both lymphoid tissues and the liver were significantly increased
inMap3k8–/–mice compared to WTmice (Fig 1G, middle row).Map3k8-deficiency also
increased the frequency of Il4gfp+Foxp3rfp+ cells in the MLN.
Pharmacological inhibition of MEK1/2, a downstream target of TPL-2, protected mice from
bleomycin induced fibrosis [31]. We have previously reported that bleomycin-induced fibrosis
is mediated by a pro-inflammatory type-1/type-17 and TGFβ driven response, distinct from
type-2 mediated pulmonary fibrosis[30]. It therefore remained unclear whether TPL-2 contrib-
uted to type-2 driven pulmonary fibrosis. To test this we treated mice intravenously with S.
mansoni eggs to invoke type-2 inflammation in the lungs leading to the development of pulmo-
nary fibrosis, as previously described [30]. Similar to responses in the liver,Map3k8–/–mice had
increased collagen staining in the lung and increased hydroxyproline levels, compared to WT
mice given S.mansoni eggs (S2 Fig). In the lung tissue and local draining thoracic lymph nodes
(TLN),Map3k8–/–mice had increased Th2 cell frequency (S2 Fig) promoting increased Il13,
Col6 and Mmp12 expression in the lung (S2 Fig). Collectively, these data indicate that TPL-2 is
an important negative regulator of type-2 inflammation, immunopathology and fibrosis fol-
lowing S.mansoni infection or S.mansoni egg induced pulmonary fibrosis in vivo.
T cell-intrinsic TPL-2 does not regulate TH2-mediated immunopathology
following S.mansoni infection
It has previously been reported that T cell-intrinsic TPL-2 regulates TH2 cell differentiation in
vitro and acute type-2 inflammation in the airways [35], however it has remained unclear
whether T cell-intrinsic TPL-2 regulates TH2 cell differentiation and function in vivo. To for-
mally test whether T cell-intrinsic TPL-2 contributed to the enhanced inflammation and fibro-
sis observed inMap3k8–/–mice (Fig 1) we restrictedMap3k8 deficiency to T cells using
Cd4CreMap3k8fl/fl mice. Deletion ofMap3k8 in T cells (Cd4CreMap3k8fl/fl) had no impact on
methods. E) Expression ofCol3 andCol6was determined from RNA extracted from liver or small intestinal tissue. Data is
expressed relative to HPRT. F) Hydroxyproline was quantified in liver tissue from naïve and infected animals. G)
Frequency of TREG (CD4
+CD25+Foxp3RFP+) and TH2 (CD4
+CD44+Il4GFP+) cells in the spleen, mesenteric lymph nodes
(MLN) and liver were determined by FACS. All experiments are representative of 2–3 independent experiments with
5–10 mice/genotype. * p< 0.05 as assessed by two-tailed Mann-Whitney test.
doi:10.1371/journal.ppat.1005783.g001
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granuloma development in the liver (Fig 2A and 2B) or small intestine (Fig 2C) following S.
mansoni infection. Similarly, fibrosis (Fig 2A and 2C) and expression of collagen synthesising
genes, Col3 and Col6, were not affected following the deletion ofMap3k8 in CD4+ cells (Fig
2D). IL-5 and IL-10 production was significantly increased in re-stimulated MLN cells from
Map3k8–/–mice, compared to WT cells; however production of these cytokines was not affected
whenMap3k8 was deleted in T cells only (Fig 2E). IL-17 production was low and unchanged
between all groups, however IFNγ secretion from lymph node cells was reduced inMap3k8–/
–mice and Cd4CreMap3k8fl/fl mice, in line with a previous report [18]. To further test whether T
cell intrinsic TPL-2 was required for TH2 cell differentiation, we isolated naïve T cells (TCRβ
+-
CD4+CD44_) fromWT andMap3k8–/–mice and polarised them under TH1 or TH2 conditions
in vitro. Similar frequencies of IFNγ+ or IL-4+ cells were observed between WT andMap3k8–/
–T cells, respectively (Fig 2F), suggesting that T cell-intrinsic TPL-2 does not contribute to TH1
or TH2 differentiation in vitro. Taken together, these data indicate that T cell-intrinsic TPL-2 is
required for optimal IFNγ secretion in vivo, but does not contribute to TH2 cell differentiation
in vitro or in vivo, and that T cell-intrinsic TPL-2 does not contribute to TH2 cell-mediated
immunopathology following S.mansoni infection.
Myeloid cell-intrinsicMap3k8 critically regulates TH2-mediated
immunopathology
Alternatively activated macrophages (AA or M2-MF) contribute significantly to inflammation,
immunopathology and fibrosis following S.mansoni infection [12]. TPL-2 has a well-defined
role in classically activated MF’s (M1 or CA-MF) [17, 20–29], however it is unclear whether
TPL-2 contributes to M2-MF following S.mansoni infection. Firstly, to test whether myeloid
cell-intrinsic TPL-2 contributed to the exacerbated immunopathology observed inMap3k8–/
–mice, we restrictedMap3k8 deletion to Lysozyme M-expressing cells using LysMCreMap3k8fl/fl
mice (S3 Fig). Mice with myeloid cell-specific deletion ofMap3k8 had significantly more
inflammation with larger hepatic (Fig 3A and 3C) and intestinal (Fig 3B) granulomas and
more severe intestinal pathology (Fig 3D), without any appreciable change in serum LPS (S3
Fig). Of note, a distinct collagen-rich fibrotic ring surrounded hepatic granulomas in LysMCre-
Map3k8fl/fl mice, which was absent in mice with WT myeloid cells. Increased collagen staining
in the liver was supported by increased expression of collagen-synthesising genes, Col3 and
Col6 (Fig 3E) and increased hydroxyproline (Fig 3F). Similar toMap3k8–/–mice, mice with
myeloid cell-specific deletion ofMap3k8 had elevated type-2 cytokine secretions (IL-13, IL-5
and IL-10) following lymph node re-stimulation without any appreciable change in IFNγ or
IL-17A secretion (Fig 3E). Similarly, elevated expression of Il13 but not Il1b, Tgfb, Il17a, Ifng,
Tnfa or Il6 was observed in LysMCreMap3k8fl/fl mice, compared to control mice (S3 Fig). These
data clearly indicated that macrophage/myeloid cell intrinsic-TPL-2 contributed significantly
to the regulation of TH2-mediated inflammation and fibrosis following S.mansoni infection.
Map3k8 regulates M2 macrophage activation
TH2-cell derived IL-4 and IL-13 [6] activates IL-4 receptor (IL-4R)-expressing MF’s [7, 8] to pre-
vent lethal pathology following S.mansoni infection. To determine whether myeloid cell-intrin-
sic TPL2 contributed to M2-MF’s activation in vivo, we isolated MF’s ex vivo from infected
mice. Chimeric mice were generated following the observation thatMap3k8–/–mice and LysMCre-
Map3k8fl/flmice had significantly elevated type-2 inflammation and fibrosis, compared to WT
controls (Figs 1 and 3). Generating 50:50 chimeric mice by reconstituting lethally irradiatedWT
mice with 50% bone marrow from CD45.1+WTmice and 50% bone marrow from CD45.2+
Map3k8–/–mice (Fig 4A), normalised and controlled for these environmental differences allowing
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Fig 2. T cell-intrinsicMap3k8 does not contribute to exacerbated inflammation and pathology following S.mansoni infection.
Cd4CreMap3k8+/+ andCd4CreMap3k8fl/flmice were infected percutenously with 50 S.mansoni cercariae and analysed at 8 weeks post-
infection. A–C) Perfused tissue was fixed and embedded in paraffin before sectioning and staining with Masson’s trichrome. B) Granuloma
size was determined from 10–20 individual granulomas per sample measured using Image J. D) Expression of Col3 andCol6was
determined from RNA extracted from liver or small intestinal tissue. Data is expressed relative to HPRT and shown as a fold-change
relative to uninfected mice. E) Mesenteric lymph node cells were re-stimulated with anti-CD3 for 3 days. Cytokines were measured in
supernatants, by ELISA. F) Naive T cells (CD4+CD44−CD25−CD62L+) were FACS purified fromWT andMap3k8–/–mice and cultured
under TH1 and TH2 conditions. Frequencies of CD44
+IFNγ+ and CD44+IL-4+ cells were determined by intracellular FACS analysis on day
7. All experiments are representative of 2–3 independent experiments with 5–10 mice/genotype. * p< 0.05 as assessed by two-tailed
Mann-Whitney test.
doi:10.1371/journal.ppat.1005783.g002
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Fig 3. Myeloid cell (LysM+) expression of Map3k8 regulates TH2-mediated immunopathology and fibrosis following S.
mansoni infection. LysMCreMap3k8+/+ and LysMCreMap3k8fl/flmice were infected percutenously with 50 S.mansoni cercariae and
analysed at 8 weeks post-infection. A–B) Perfused tissue was fixed and embedded in paraffin before sectioning and staining with
Masson’s trichrome. Scale bar is 200μm. C) Granuloma size was determined from 10–20 individual granulomas per sample
measured using Image J. D) Intestinal pathology score, as described in methods. E) Expression of Col3 andCol6was determined
TPL-2 Regulates Fibrosis
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us to more accurately compareWT andMap3k8–/–MF’s ex vivo. Following 8-weeks of S.man-
soni infection, CD45.1+WT or CD45.2+Map3k8–/–CD3−CD11b+F4/80+CD11b+ MF’s were
FACS sorted for analysis (Fig 4A).Map3k8–/–MF’s had significantly lower expression of Arg1,
Relma and Chi3l3, compared to WTMF’s isolated form the same tissue (Fig 4B). In addition,
Map3k8–/–MF’s had elevated expression of collagen synthesising genes (Col1, Col3) and connec-
tive tissue growth factor (Ctgf). These data indicate that macrophage cell-intrinsic TPL2 was
required for M2-MF activation and regulated expression of pro-fibrotic genes.
To determine how TPL-2 was regulating M2-MF activation we used the well-described in
vitromacrophage activation assay, activating bone marrow-derived MF’s (BMDM) with IL-4
and IL-13. Following 6hrs of exposure to IL-4 and IL-13, Arg1, Retnla, Chi3l3 and Ear11 were
all significantly reduced inMap3k8–/– M2-MF’s, compared to WTM2-MF’s (Fig 5A–5D),
similar to that observed in ex vivo MF’s. At 24hrs, Retnla, Chi3l3 and Ear11 were still signifi-
cantly reduced inMap3k8–/– M2-MF’s, demonstrating a non-redundant role for TPL-2 in
M2-MF activation. The early reduction of Arg1 expression inMap3k8–/– M2-MF’s led to a
reduction in arginase activity with reduced ornithine production, as determined by LCMS (S4
Fig). Inhibition of the kinase activity of TPL-2, using the pharmacological inhibitor, C34 [37],
phenocopiedMap3k8–/–MF’s indicating that the kinase activity of TPL-2 was responsible for
the reduced Retnla expression in M2-MF (S4 Fig). Phosphorylated (p)STAT6, pERK, pp38α
and pJNK were similar inMap3k8–/–andWTMF’s (Fig 5E), suggesting that TPL-2 did not reg-
ulate responsiveness of MF’s to IL-4 and/or IL-13 and was not required for activation of these
downstream transcription factors or kinases.
To determine whether TPL-2 regulated the expression of other genes, beyond the character-
istic M2-MF-associated genes, we profiled the transcriptional landscape of WT andMap3k8–/
–MF’s following 24hrs of IL-4 and IL-13 stimulation (Fig 6A). Pathway analysis identified
increased inflammatory pathways inMap3k8–/– M2-MF’s, including proliferation, migration
and fibrogenesis (Fig 6B). Of the significantly differentially regulated genes (P<0.05,> 2-fold,
relative to un-stimulated) (Fig 6C), we identified 351Map3k8-dependent genes (i.e. genes dif-
ferentially regulated in WT only, Fig 6C and 6D) and 279Map3k8-regulated genes (i.e. genes
differentially regulated inMap3k8–/–MF’s only, Fig 6C and 6F). Of note, several of these ele-
vated genes inMap3k8–/– M2-MF’s contribute to fibrogenesis, including Adam19 [38], Cxcr4
[39],Mmp13 [40], Cav1 [41], Itgav [42] and Vcam1 [43] (Fig 6F). Of the commonly regulated
genes in both WT andMap3k8–/–M2-MF’s (Fig 6E and 6G)Map3k8–/–M2-MF’s had elevated
expression of collagen-synthesising genes (Col1a1, Col3a1, Col5a2) and the connective tissue
growth factor, Ctgf (Fig 6H) compared to WTMF’s (Fig 6G). Concurrent with increased
expression of pro-fibrotic genes, characteristic M2-MF genes (Retnla, Arg1, Ear11 (Rnase2)
and Chi3l3) were reduced, compared to WTM2-MF’s (Fig 6H). Taken together, these in vitro
gene expression data suggested thatMap3k8–/– M2-MF’s had both elevated pro-fibrotic prop-
erties and reduced regulatory/inhibitory functions (Arg1 and Retnla (Figs 4 and 5)).
Map3k8 regulates lipolysis for proficient alternative activation of
Macrophages
Oxidative lipid metabolism is a metabolic programme recently reported to be essential for
M2-MF activation [44]. It also has previously been reported that TPL-2, MEK 1/2 and ERK 1/2
from RNA extracted from liver. Data is expressed relative to HPRT and presented as a fold-change relative in infectedWTmice. F)
Hydroxyproline was quantified in liver tissue from naïve and infected animals. G) Mesenteric lymph node cells were re-stimulated
with anti-CD3 for 3 days. Cytokines were measured in supernatants, by ELISA. All experiments are representative of 2–3
independent experiments with 5–10 mice/genotype. * p< 0.05 as assessed by two-tailed Mann-Whitney test.
doi:10.1371/journal.ppat.1005783.g003
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Fig 4. TPL-2 is required for M2 activation of Macrophages, in vivo.WTC57BL/6 mice were lethally irradiated (900rad)
and reconstituted with 50% CD45.1+WT bone marrow and 50%CD45.2+Map3k8–/–bone marrow and left for 6–8 weeks,
prior to infection with 50 S.mansoni cercariae. A) After 8 weeks of infection, mice were sacrificed and
CD3−CD19−CD11b+F4/80+ Macrophages were FACS-sorted. B-C) Expression of Arg1, Relma, Chi3l3, Col1a1, Col3a1 and
Ctgf was determined from RNA extracted from purified macrophages. Data is expressed relative to HPRT and presented as
a fold-change relative in genotype-controlled naïve bone marrow derived macrophages. Experiments are representative of
2 independent experiments with 5 mice/genotype. * p< 0.05 as assessed by two-tailed Mann-Whitney test.
doi:10.1371/journal.ppat.1005783.g004
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Fig 5. TPL-2 is required for M2 activation of Macrophages, in vitro. A-D) Bone marrow-derived macrophages (BMDM)
were stimulated with IL-4 and IL-13 for 6 or 24 hours, as indicated. Cells were harvested, RNA extracted and gene expression
was determined by qRT—PCR and expressed relative to un-stimulated genotype control cells. E) BMDM’s were stimulated for
1.5, 3 and 6 hours, as indicated. Total Protein was extracted with phosphorylated and total protein levels of STAT6, ERK, p38a,
JNK and α-tubulin determined by western blot. All experiments are representative of 2–3 independent experiments with 3–5
biological replicates and 3 technical replicates in each experiment. * p< 0.05 as assessed by two-tailed Mann-Whitney test.
doi:10.1371/journal.ppat.1005783.g005
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[45–48] can regulate lipid metabolism in a variety of different cells. We therefore hypothesised
that the compromised M2-MF activation ofMap3k8-deficient MF’s was due to reduced lipid
metabolism. To investigate this possibility, we analysed the expression of 220 genes involved in
lipid metabolism from the transcriptional data obtained fromWT andMap3k8–/–M2-MF ‘s
(S1 Table) and identified 16 TPL-2-dependent genes involved in lipid metabolism that were up
regulated inWTM2-MF’s but not inMap3k8–/– M2-MF’s (Fig 7A). These genes included the
LDL receptor, Olr1, which is required for lipid uptake [49] and Adipoq encoding adiponectin,
which promotes lipid oxidation [50] and the alternative activation of humanMF’s [51]. In addi-
tion, Aldh1a2 (also referred to as Raldh2) which catalyses the synthesis of the lipid metabolism-
promoting metabolite, retinoic acid, from retinaldehyde [52] and the NFκB-regulated sialyl-
transferase, St8sia1 [53], which catalyzes the transfer of sialic acid from CMP-sialic acid to GM3
to produce gangliosides, were reduced inMap3k8–/–M2-MF’s, compared to WTM2-MF’s.
Several of these genes are downstream of TPL-2 (S5 Fig), supporting our hypothesis that TPL-2
regulates lipolysis in M2-MF’s. Together these changes in gene expression inMap3k8-deficient
M2-MF’s were consistent with TPL-2 signalling regulating lipolysis.
To formally test whether lipid metabolism was compromised inMap3k8–/–M2-MF’s, we
used extracellular flux analysis and measured the oxygen consumption rate (OCR) and spare
respiratory capacity (SRC, the quantitative difference between maximal uncontrolled OCR, and
the initial basal OCR, indicative of commitment to oxidative phosphorylation) in un-stimulated
and IL-4/IL-13 mediated M2-MF’s. At baseline, un-stimulatedWT andMap3k8–/–MF’s had a
similar OCR and SRC (S6 Fig). However,Map3k8–/– M2-MF’s had significantly reduced OCR
and SRC (Fig 7B and 7C), indicating that TPL-2 is required for lipid metabolism in M2-MF’s,
and providing a mechanistic explanation for reduced M2-MF’s inMap3k8–/–mice.
Map3k8–/–mice and LysMCreMap3k8fl/fl mice, which had compromised M2-MF activation,
had elevated Th2 cell responses. It has previously been reported that M2-MF’s can directly reg-
ulate T cell responses [13–15]. We therefore hypothesised thatMap3k8–/– M2-MF’s would not
regulate Th2 cell differentiation and proliferation as well as WTM2-MF’s. To test this hypoth-
esis, we co-cultured WT orMap3k8–/–BMMF’s with naïve cell trace violet (CTV)-labelled
CD4+CD44−Il4gfp–OTII+ T cells in the presence of IL-4, IL-13 and OVA and determined the
proliferation (CTV dilution) and differentiation (Il4gfp expression) of T cells. After 3 days, 24%
of T cells had proliferated and differentiated when co-cultured with WTMF’s (Fig 7D, top row
middle panel). However, co-culture of T cells withMap3k8–/–MF’s led to significantly more
Th2 cell differentiation and proliferation (~38%, Fig 7D, bottom row middle panel). Finally, to
determine whether lipid metabolism contributed to MF-mediated regulation of Th2 cell prolif-
eration and differentiation we pre-treated MF’s for 6 hours with Orlistat, an irreversible lipase
inhibitor, prior to co-culture with T cells. Orlistat treated WTMF’s led to more Th2 cell prolif-
eration and differentiation (~32%, Fig 7D, top row right panel), phenocopyingMap3k8–/–MF’s
and indicating that lipid metabolism in IL-4/IL-13 activated MF’s was required for optimal
MF-mediated control of Th2 cell proliferation, as previously reported [44]. Of note, Orlistat
treatedMap3k8–/–MF’s only led to a small increase in Th2 cell proliferation, suggesting that
lipid metabolism was already at a minimum inMap3k8–/–MF’s.
Taken together this study has demonstrated that TPL-2 is a critical regulator of immune-
mediated pathology and fibrosis following S.mansoni infection, functioning as an important
metabolic regulator in M2-MF activation.
Discussion
Liver fibrosis and cirrhosis, which is responsible for over 1.5 million fatalities per year [54], can
develop following a variety of infectious insults, including chronic infection [4]. Diseases
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Fig 6. TPL-2 regulates pro-fibrotic and immuno-regulatory pathways in M2macrophages. Bone marrow-derived
macrophages (BMDM) were stimulated with IL-4 and IL-13 for 24 hours. Cells were harvested, RNA extracted and genome-wide
transcriptional expression was determined by microarray analysis using 3 biological replicates. A) Heat map of differentially
regulated genes in un-stimulated and IL-4+IL-13 stimulated cells. B) Ingenuity pathways analysis of transcriptional profiles of
differentially regulated genes. C-F) Venn diagram and bar graphs of TPL-2 dependent (1), common (2) and TPL-2-regulated genes
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characterized by persistent TH2 cytokine responses, such as chronic helminth infections, are
associated with the development of significant tissue pathology and fibrotic scarring. Although
the molecular pathogenesis of fibrotic diseases are slowly emerging [4], there are very few
novel therapeutic candidates progressing through clinical trials [55], highlighting a significant
unmet medical need.
Two distinct inflammatory axes contribute to inflammation-driven fibrosis; type-1/ TH17
mediated inflammation [30] and type-2 driven fibrosis [56]. In this study we established that
the Map3 kinase, TPL-2, is an important negative regulator of chronic type-2 inflammation-
driven fibrosis following schistosome infection. These data are in contrast to a previous study
testing the role of TPL-2 in three models of pro-inflammatory type-1/17-associated fibrosis
(carbon tetrachloride-, methionine-choline-deficient diet- and bile duct ligation-induced fibro-
sis)[57, 58]. In two of these three modelsMap3k8–/–mice had significantly reduced fibrosis
[32]. These seemingly contrasting results most likely reflect the different inflammatory events
contributing to the fibrogenic response. For example, it has been widely reported that TPL-2 is
required for pro-inflammatory type-1/17-associated inflammation and immunity [17–29]. It
therefore stands to reason that TPL-2 would be required for pro-inflammatory type-1/17-asso-
ciated fibrosis, as reported by Perugorria and colleagues [32]. In contrast, TPL-2 appears to
function as a negative regulator of type-2 inflammation in the lung and liver (Fig 1, S2 Fig),
with increased acute [35] and chronic type-2 inflammation inMap3k8–/–mice, as presented
here. In this context, the exacerbated type-2 inflammatory response inMap3k8–/–mice resulted
in increased fibrosis. If these animal models reflect human disease, focused strategies targeting
TPL-2 would benefit from identifying a prognostic biomarker and treating patients with type-
1/17-associated fibrosis, rather than patients with type-2-associated fibrosis.
Inflammation-driven fibrosis involves a co-ordinated and often dysregulated wound healing
response involving a variety of migratory leukocytes activating local stroma. TPL-2 is expressed
in both leukocytes and local stroma and therefore identifying where TPL-2 was regulating the
fibrogenic process was essential for us to identify how TPL-2 regulated fibrosis. It has been pre-
viously suggested that increased acute TH2 responses inMap3k8
–/–mice was due to a T cell-
intrinsic role for TPL-2 [35], however this was not tested in vivo. Similarly, increased intestinal
inflammation and tumorigenesis inMap3k8–/–mice was attributed to a reduced frequency of
Foxp3+ TREG cells, [36], however again this was not specifically tested in vivo. UsingMap3k8
–/
–Il4gfpFoxp3rfp mice and re-stimulated local lymph nodes we identified that TPL-2 negatively
regulated the differentiation, expansion and/or recruitment of TH2 cells, however this was not
due to a T cell-intrinsic role for TPL-2, as mice with a T cell-intrinsic deletion ofMap3k8
mounted similar TH2 responses as WT mice. Furthermore, exacerbated hepatic fibrosis
observed inMap3k8–/–mice was not observed in mice with a T cell-specific deletion of
Map3k8, indicating that T cell-intrinsic TPL-2 had no impact on type-2–mediated inflamma-
tion or fibrosis in these systems.
TPL-2 has been extensively studied in TLR-mediated classical macrophage activation (CA,
M1-MF) [20]. However, it was unclear whether TPL-2 contributes to M2-MF differentiation.
M2-MF’s are central regulators of inflammation, wound-healing and fibrosis following schis-
tosome infection [12]. Specifically, Arginase (Arg-1) in M2-MF’s catalyses the cleavage of argi-
nine to ornithine and urea, depleting extracellular arginine and depriving local leukocytes of
this essential amino acid. Consequently, M2-MF’s limit T cell proliferation, by starvation, in
an Arg-1-dependent manner [14]. Similarly, production of Retnla by M2-MF’s can suppress T
(3). G and H) Ratio of Ratios graph (top) and bar graphs (H) showing increased pro-fibrotic (red) and decreased Immunoregulatory
(blue) genes inMap3k8–/–macrophages, relative to WTmacrophages (x-axis) and un-stimulated macrophages (y-axis).
doi:10.1371/journal.ppat.1005783.g006
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Fig 7. TPL-2 regulates lipolysis in M2macrophages and regulation of TH2 cell differentiation and proliferation. Bone
marrow-derived macrophages (BMDM) were stimulated with IL-4 and IL-13 for 24 hours. A) Analysis of genes involved in lipid
metabolism was performed by Ingenuity pathways analysis (S1 Table) withMap3k8-dependent genes depicted in a heat map. B)
After 24hrs of stimulation with IL-4 and IL-13 oxygen consumption rates (OCR) were determined in M2 macrophages using an XF-
96 Extracellular Flux Analyzer (EFA) during sequential treatments with oligomycin, FCCP, and rotenone/antimycin. Spare
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cell responses directly [13, 15]; highlighting two mechanisms by which M2-MF’s regulate TH
cell responses. The reduced expression of these immunoregulatory molecules (Arg1 and
Retnla) inMap3k8–/– M2-MF’s may therefore explain the elevated TH2 cell inflammation
observed inMap3k8–/–mice. Indeed,Map3k8–/– M2-MF’s did not control TH2 cell differentia-
tion or proliferation (Fig 7D).
M2-MF’s also supply proline for collagen synthesis and produce a variety of pro-fibrotic fac-
tors to promote wound healing, collagen deposition and if dysregulated, fibrotic scarring [59].
We observed increased expression of pro-fibrotic genes (Col1a1, Col3a1, Col5a2 and Ctgf) in
Map3k8–/–M2-MF’s, which may explain the elevated fibrosis observed inMap3k8–/–mice. The
mechanism of TPL-2-mediated regulation of pro-fibrotic mediators is not completely under-
stood. It was recently reported that TPL-2 regulates hepatocyte growth factor (HGF) production
in fibroblasts [60], in part, by reducing sensitivity to TGFβ. In IL-13-dependent fibrosis, TGFβ
can inhibit some pro-fibrotic pathways [33]. IfMap3k8-deficient M2-MF’s also have decreased
sensitivity to TGFβ, this may explain the increased expression of several pro-fibrotic mediators
inMap3k8-deficient M2-MF’s, however this requires further study. Together, these two obser-
vations provide some explanations for the increased TH2 cell responses and exacerbated hepatic
and pulmonary fibrosis observed inMap3k8–/–mice. Indeed, specific deletion ofMap3k8 in
LysM-expressing cells phenocopiedMap3k8–/–mice, with increased TH2 inflammation and
fibrosis following S.mansoni infection or S.mansoni egg injection, compared toWTmice. The
LysMCre system appears to efficiently delete floxed alleles in tissue-resident MF’s, but not so well
in newly recruited myeloid cells [61, 62]. The exacerbated immunopathology observed in LysM-
CreMap3k8fl/fl mice suggests thatMap3k8may have an important function in tissue-resident
MF’s, rather than newly recruited myeloid cells that may not have efficiently deletedMap3k8.
Exactly how TPL-2 regulates IL-4R-driven M2-MF activation is unclear. TPL-2, and down-
stream kinases, MEK 1/2 and ERK 1/2 are required for lipid metabolism [45–48], a metabolic
programme recently identified to be essential for M2-MF [44]. Joining these two independent
observations, we confirmed that TPL-2 was an essential regulator of lipid metabolism in
M2-MF’s, with extracellular flux assays identifying reduced oxygen consumption and reduced
spare respiratory capacity, compared to WTM2-MF’s. The decreased lipid metabolism in
Map3k8–/– M2-MF’s provides an explanation for the decreased expression of immunoregula-
tory molecules [44] inMap3k8–/– M2-MF’s. In addition,Map3k8–/– M2-MF’s had reduced
expression of several genes encoding enzymes involved in lipid uptake, lipid metabolism and
synthesis (Fig 6), providing an explanation as to how lipid metabolism may be compromised in
Map3k8–/– M2-MF’s. Thus, we speculate that following IL-4R-signalling and STAT-6-medi-
ated activation of downstream gene products, TPL-2 is required for the necessary metabolic re-
programming [44] for optimal M2-MF activation.
A paralleled increase in pro-fibrotic factors inMap3k8–/– M2-MF’s identified a novel TPL-
2-regulated pro-fibrotic axis in M2-MF’s. Whether this was also due to compromised meta-
bolic programme inMap3k8–/– M2-MF’s is currently unclear. In vivo, the increased TH2-me-
diated inflammation, as a result of compromised immune regulation byMap3k8–/– M2-MF’s,
may further exacerbate pro-fibrotic pathways, providing a severely dysregulated
respiratory capacity (SRC), the quantitative difference between maximal uncontrolled OCR, and the initial basal OCR, is depicted
in the plot. C) Basal oxygen consumption rates (OCR) and spare respiratory capacity (SRC) in WT andMap3k8–/–M2
macrophages. D) WT or Map3k8-deficent bone marrow-derived macrophages (BMDM) were generated from 3 individual mice and
co-cultured with a pool of cell trace Violet (CTV)-labelled naïve OTII CD4+CD44−Il4gfp–T cells and stimulated with IL-4 and IL-13 for
3 days. Th2 cell differentiation (Il4gfp expression) and proliferation (CTV dilution) was determined by FACS after 3 days. In some
wells BMDMwere pre-treated with Orlistat for 6 hours and washed, prior to co-culture. Data is representative of 2–3 independent
experiments with a minimum of 3 biological replicates per experiment. * p< 0.05 as assessed by two-tailed Mann-Whitney test.
doi:10.1371/journal.ppat.1005783.g007
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microenvironment. In summary, this study has identified that TPL-2 is an important metabolic
regulator in M2-MF’s in vitro and that myeloid cell intrinsic TPL-2 critically controlled
chronic type-2-mediated inflammation and fibrosis in vivo.
Materials and Methods
Animals
All mice were bred and maintained under specific pathogen-free conditions at The Francis
Crick Institute. Strains used included: WT C57BL/6,Map3k8–/–[20], OTII [63], Il4gfp [64],
Foxp3rfp[65], Cd4CreMap3k8flflR26eYFP (B6.Cd4Cre [66] crossed with Map3k8flfl and B6.
R26eYFP), LysMCreMap3k8flflR26eYFP (B6.LysMCre [67] crossed with Map3k8flfl and B6.R26eYFP).
S.mansoni infection and egg-induced pulmonary inflammation
Mice were infected percutaneously via the tail with 50 cercariae of a Puerto Rican strain of S.
mansoni (NMRI) obtained from Biomphalaria glabrata snails, kindly provided by Dr. Quentin
Bickle, LSHTM. Infection intensity was determined following perfusion and granuloma size was
determined from 10–20 individual granulomas per tissue sample, measured using Image J. Tis-
sue pathology was analysed following Masson’s trichrome (Collagen, Blue; Nuclei, black/dark
blue; Muscle, cytoplasm, Red) staining of 5μm sections from paraffin embedded samples. Intes-
tinal pathology was determined using a comprehensive scoring system taking into account the
level of infiltration, disruption and severity of the intestinal architecture [68]. Hydroxyproline
content was quantified in liver tissue using a hydroxyproline assay kit according to the manufac-
turers recommendations (Cambridge Biosciences, UK). Tissue eggs were quantified by digesting
a known weight of liver tissue with collagenase and liberase and isolating eggs on a discontinu-
ous percoll gradient, as previously described [69]. For intravenous delivery of S.mansoni eggs,
eggs were washed extensively in PBS, with 5000k delivered in 200μl of sterile PBS.
Bone marrow derived macrophage culture
Bone marrow cells were plated to a density of 5 x 106 cells per 90-mm bacterial Petri dish (Ster-
ilin) in 10ml of DMEM/F-12 Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 with
GlutaMAX supplement (Gibco) supplemented with 10% FBS, antibiotics, 20% L-cell condi-
tioned medium, L-Glutamine (1%), HEPES (1%), Sodium Pyruvate (1%) and β-mercaptoetha-
nol (1%). After 4 days of culture, 10ml of additional medium was added and cells were cultured
for a further 3 days. Non-adherent cells were washed away and the adherent cells were collected
in 5ml PBS with 5% FBS and 2.5mM EDTA. For experiments the cells were re-plated in
medium with 1% FBS without L-cell supplement and were incubated overnight before stimula-
tion. Cells were stimulated with IL-4 and IL-13 (20ng/ml) (R&D systems) or LPS (100ng/ml)
(Alexis Biochemicals). In some experiments, BMDM were generated from three individual
mice and co-cultured with a pool of naïve OTII CD4+CD44−Il4gfp–T cells during stimulation
with OVA peptide (323–339) (Invivogen). In some of these co-culture experiments, BMDM were
pre-treated for 6 hours with Orlistat (100μM; Cayman), prior to co-culture.
Isolation of hepatic macrophages
Liver tissue was perfused and the organ was collected in gentleMACS columns (Miltenyi Bio-
tec) in incomplete RPMI 1640 (Gibco). The tissues were dissociated in incomplete RPMI 1640
with Liberase TL (0.5mg/ml) (Roche), Collagenase (4μg/ml) (Roche) and DNAse (7.5μg/ml)
using the gentleMACS dissociator (Miltenyi Biotec). The partly digested tissue fragments were
incubated at 37°C for 45 min, following which the tissues were completely dissociated. The
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cellular fraction was run through a 100μm filter and the cells were centrifuged at 50g for 3 min,
to pellet the non-parenchymal cells and the supernatant fraction was centrifuged at 320g for
5min. The cellular fractions from both steps were pooled and collected in 1X HBSS Hanks bal-
anced salt solution and mixed with OptiPrep (Sigma) to get a 17% w/v solution and overlayed
with 1X GBSS Gey’s balanced salt solution. The samples were centrifuged at 400g for 15min at
room temperature with no brakes and the enriched layer of cells were collected from the inter-
face of the GBSS and the 17% solution. The cells were stained and FACS sorted as Live/
CD45+/CD3−/CD19−/NK1.1−/Ly6G−/SiglecF−/CD11b+/F4/80+.
Metabolism assays
Day 7 bone marrow-derived monocytes (BMDM) were cultured at a density of 5x105 cells in an
XF24 plate (Seahorse Bioscience) over night. On day 8 cells were stimulated with 20ng/ml of
recombinant IL-4 and IL-13 (R&D systems). On day 9 media was replaced with XF base medium
(Seahorse Bioscience) supplemented with 100x Glutamax (Gibco), 100X Sodium Pyruvate
(SIGMA) and 25mM glucose and the plate incubated for 10–30 minutes in a non-CO2 incubator
at 37°C. For analysis of basal oxygen consumption rate (OCR) and extracellular acidification rate
(ECAR), cells were analysed with XF-24 Extracellular Flux Analyzer (Seahorse Bioscience) under
standard Seahorse running protocol. The Seahorse cartridge was loaded at a final concentration
of 10μMOligomycin (SIGMAO4876-5mg), 15μMFCCP (triflourocarbonylcyanide phenylhy-
drazone, SIGMA C2920-10mg), 1μMRotenone (SIGMA R8875) plus 10μMAntimycin A
(A8674-25mg) in ports A, B and C respectively. The bioenergetics profile consisted of basal OCR
measurements in the absence of drugs and OCR/ECAR following the injection of drugs. All
OCR/ECAR/SRC analyses were obtained from 5 replicates in 3 independent repeats.
LC-MS for arginase assay. At day 7, non-adherent cells were washed away and the adher-
ent cells were collected in 5ml PBS with 5% FBS and 2.5mM EDTA. Cells were re-plated in
medium with 1% FBS without L-cell supplement in a 6-well plate. Cells were kept for 12–18
hours, then stimulated with IL-4 and IL-13 (20ng/ml) (R&D systems) for 24hrs. Cells were
washed twice with PBS, metabolites were extracted with ice cold mixture of acetonitrile/metha-
nol/water (2:2:1, v/v/v). Plates were kept on dry ice for 5–10 min. Cells were collected, vortexed
vigorously then spun for 20 min at 16,000g at 4°C. The supernatant was stored at -80°C until
analysis. Residual protein content in the cell lysates was determined with Bicinchoninic acid
method (BCA assay, Pierce). Prior to the LC-MS analysis, 100μL of the cell lysates were acidi-
fied with an equal volume of acetonitrile containing 0.2% acetic acid. The mixture was spun for
10 minutes at 16,000g, at 4°C. 2μL of the acidified mixture were used for the LC-MS analysis.
Chromatography was performed on Agilent 1200 LC system, including a solvent degasser,
binary pump and temperature-controlled auto-sampler. Samples were inject to a Cogent Dia-
mond Hydride Type C silica column (150mm×2.1mm i.d, 4μm particle size and 100A pore
size) and eluted with flow rate of 0.4 mL/min. The gradient employed is based on the number
3, according to [70]. Metabolites were detected using an Agilent Accurate Mass 6230 TOF
apparatus, as previously described [71]. Detected m/z 175.11895 at 16.8 min and 133.0972 at
16.6 min were identified as arginine and ornithine, respectively, on the basis of unique accurate
mass-retention time identifiers and spectral data. The reported abundances were normalized to
the residual protein content in each corresponding sample.
TH2 polarization and re-stimulation of lymph node cells ex-vivo
Naive CD4+ T cells (CD4+TCRβ+CD44−CD25−PI−) were FACS-purified from spleens of WT
orMap3k8–/–mice. Naive T cells were cultured for 6 days in vitro with 10ng/mL IL-4 (R&D),
5ng/mL IL-2 (R&D), 10 μg/mL anti-IFNγ (XMG1.2, BioXcell), and CD3 (0.1–4.0μg) (145-
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2C11, BioXcell) and CD28 (10μg/ml) (37.51, BioXcell) in complete IMDM (cIMDM, 10% fetal
calf serum (FCS),100 U/mL Penicillin and 100 μg/mL Streptomycin (Gibco), 8mM L-gluta-
mine (Gibco), and 0.05mM 2-mercaptoethanol (Gibco)). For re-stimulation of lymph node
cells ex-vivo, lymph nodes were disrupted into a single cell suspension with 2x105 cells cultured
in a 96-well, round bottom plate with 10μg/ml of anti-CD3 (145-2C11, BioXcell). Supernatants
were harvested after 3 days for analysis by ELISA.
qRT-PCR, ELISA, western blotting and serum LP
qRT-PCR. Tissue samples were frozen in RNAlater (Sigma) and homogenized in QIAzol
(Qiagen). Cell pellets were lysed in Buffer RLT (Qiagen). Total RNA was isolated as per manu-
facturer’s protocol. 100ng-1μg of total RNA was reverse transcribed using the QuantiTect
Reverse Transcription Kit (Qiagen). cDNA produced was used for real time quantitative PCR
with Power SyBrGreen (Applied Biosystems). The expression levels of different genes were
normalised to hypoxanthine-guanine phosphoribosyl transferase (HPRT) expression and
expressed as fold change relative to naïve or PBS-treated WT samples.
ELISA. IL-5, IL-13, IL-10, IFNγ and IL-17 were measured using DuoSet ELISA kits,
according to the manufacturer’s instructions (R&D systems—Biotechne).
Western blotting. For immunoblotting, cell lysates were normalized to equal total protein
content and resolved on 10% Criterion TGX Gels (Biorad). Separated proteins were transferred
onto Trans-Blot Turbo PVDF transfer (Biorad) membranes (Immobilon). Specific bound anti-
bodies were visualized by chemiluminescence (Merck Millipore). Endotoxin levels in serum
samples were measured using an LAL chromogenic assay, according to manufacturer’s recom-
mendations (Pierce, Thermo fisher).
Cell sorting and flow cytometry
Cell sorting was performed using a FACS Aria II (BD Biosciences) cell sorter. For sorting, cell
suspensions were stained for 20 minutes with antibodies in PBS with 2% fetal calf serum (FCS)
and then diluted in phenol-red free IMDM (Gibco) (with 1% FCS, 2mM EDTA (Invitrogen),
100U/mL Penicillin and 100μg/mL Streptomycin (Gibco), 8mM L-glutamine (Gibco), and
0.05mM 2-mercaptoethanol (Gibco)). Propidium iodide (PI) or LIVE/DEAD fixable blue dead
cell stain (Life Technologies) was used to determine cell viability. Cells were stained for surface
antigens by incubation with antibodies in PBS with 2% FCS (20 minutes at 4°C). Intracellular
cytokine staining was performed following 6 hours re-stimulation with 50ng/mL phorbol
12-myristate 13-acetate (PMA, Promega) and 1μg/mL ionomycin (Sigma) and BD Golgi Stop
and BD Golgi Plug (diluted 1:1000, BD Biosciences). After staining for surface antigens, cells
were fixed and permeabilized (Fixation/Permeabilization diluent; eBioscience), prior to incuba-
tion with cytokine antibodies in Permeabilization buffer (eBioscience) for 20 min at 4°C. Cells
were analyzed using a BD LSRII flow cytometer (BD Biosciences) and data processed using
FlowJo software (Version X 10.0.7r2, Treestar Inc). Antibodies used were purchased with
eBioscience, Biolegend or BD Pharmingen. They included: CD45 (30-F11), CD3 (17A2), CD4
(RM4-5, GK1.5), CD11b (M1/70), CD19 (6D5, eBio1D3), CD25 (PC61), CD44 (IM7), NK1.1
(PK136), Ly6G (1A8), SiglecF (E50-2440), and F4/80 (BM8), TCR β chain (H57-597). Staining
was performed in the presence of FcR Blocking Reagent (Miltenyi Biotec).
RNA, qRT-PCR and microarray
RNA was isolated from tissues and cells using RNAeasy mini spin columns according to manu-
facturers’ instructions (Qiagen). cDNA was generated from 5ng of total RNA using WT-Ova-
tion Pico system (version 1) RNA Amplification System followed by double stranded cDNA
TPL-2 Regulates Fibrosis
PLOS Pathogens | DOI:10.1371/journal.ppat.1005783 August 3, 2016 19 / 26
synthesis using WT-Ovation Exon Module. cDNA quality was determined using an Agilent
BioAnalyzer and through hybridization performance on Affymetrix GeneChip mouse Genome
430A 2.0 microarray (Affymetrix) by the Systems Biology Unit at The Francis Crick Institute.
Microarray data were quantile-normalized and analysed using GeneSpring software (Agilent).
Differentially expressed genes were determined using ANOVA and t-tests. Genes with false
discovery rate corrected p-values less than 0.1 and fold change values1.5 were considered sig-
nificant, and as indicated in figure legends. Three biological replicates of each subset were used.
Pathways analysis was performed using Ingenuity Pathways Analysis (IPA, Ingenuity Systems,
www.ingenuity.com).
Statistical analysis
Data sets were compared by MannWhitney test using GraphPad Prism (V.5.0). Differences
were considered significant at p 0.05 using one or two-tailed tests.
Ethics statement
All animal experiments were carried out following UK Home Office regulations (project license
80/2506) and were approved by The Francis Crick Institute Ethical Review Panel.
Supporting Information
S1 Fig. TPL-2 regulated parasitology and pathology.WT andMap3k8–/–mice were infected
percutenously with 50 S.mansoni cercariae and analysed at 8 weeks post-infection. A) S.mansoni
eggs were quantified in the liver tissue as previously described [69]. B) Endotoxin levels (LPS) in
serum was determined using an LAL assay kit at necropsy. C) Expression of Il13, Il1b, Tgfb,
Il17a, Ifny, Tnfa and Il6 was determined from RNA extracted from liver tissue. Data is expressed
relative to HPRT and presented as a fold-change relative to genotype-controlled naïve mice.
(TIFF)
S2 Fig.Map3k8–/–mice develop increased S.mansoni egg-induced pulmonary fibrosis.WT
orMap3k8–/–mice were given 5000 S.mansoni eggs intravenously before necropsy at day 21.
A) Lung tissue was fixed and embedded in paraffin before sectioning and staining with Mas-
son’s trichrome. B) Hydroxyproline was quantified in liver tissue from naïve and S.mansoni
egg treated mice. C) Frequency of TREG (CD4
+Foxp3RFP+) and TH2 (CD4
+Il4GFP+) cells in the
thoracic lymph nodes (top row) and lung (bottom row) were determined by FACS on day 21.
D) Expression of Il13, Col6 and Mmp12 was determined in RNA extracted from lung tissue.
Data is expressed relative to HPRT and presented as a fold-change relative to genotype-con-
trolled naïve mice. All experiments are representative of 2 independent experiments with 5
mice/genotype.  p< 0.05 as assessed by two-tailed Mann-Whitney test.
(TIFF)
S3 Fig. Myeloid cell (LysM+) expression of Map3k8 regulates TH2-mediated immunopa-
thology and fibrosis following S.mansoni infection. LysMCreMap3k8+/+ and LysMCre-
Map3k8fl/fl mice were infected percutenously with 50 S.mansoni cercariae and analysed at 8
weeks post-infection. A) Detection of TPL-2 protein in macrophages (Live/Dead−CD45+F4/80-
+LysMCreR26eYFP+) from LysMCreMap3k8+/+ and LysMCreMap3k8fl/fl mice. B) Endotoxin levels
(LPS) in serum was determined using an LAL assay kit at necropsy. C) Expression of Il13, Il1b,
Tgfb, Il17a, Ifny, Tnfa and Il6 was determined from RNA extracted from liver tissue. Data is
expressed relative to HPRT and presented as a fold-change relative to genotype-controlled
naïve mice.
(TIFF)
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S4 Fig. TPL-2 regulated macrophage activation. A) WT andMap3k8–/–bone marrow-derived
macrophages (BMDM) were stimulated with IL-4 and IL-13 for 24 hours with cell lysates used
for arginine metabolism profiling using LC-MS. B) WT andMap3k8–/–bone marrow-derived
macrophages (BMDM) were stimulated with IL-4 and IL-13 for 24 hours in the presence of a
specific TPL-2 inhibitor, C34. Cells were harvested, RNA extracted and Retnla expression was
determined by qRT-PCR and expressed relative to un-stimulated genotype control cells.
(TIFF)
S5 Fig. TPL-2 regulated lipid metabolism pathways in M2 macrophages. Ingenuity pathways
analysis of lipid metabolism pathways (S1 Table) from bone marrow-derived macrophages
(BMDM) stimulated with IL-4 and IL-13 for 24 hours, as in Figs 5 and 6. Elevated genes
involved in lipid metabolism in WT, but notMap3k8–/–macrophages, are displayed, with their
relationship withMap3k8 highlighted via intermediate genes.
(TIFF)
S6 Fig. Lipolysis in un-stimulated WT andMap3k8–/–macrophages. Bone marrow-derived
macrophages (BMDM) were generated and left un-stimulated for 24 hours. A) Oxygen con-
sumption rates (OCR) were determined using an XF-96 Extracellular Flux Analyzer (EFA)
during sequential treatments with oligomycin, FCCP, and rotenone/antimycin. Spare respira-
tory capacity (SRC), the quantitative difference between maximal uncontrolled OCR, and the
initial basal OCR, is depicted in the plot. B) Basal oxygen consumption rates (OCR) and (C)
spare respiratory capacity (SRC) in WT andMap3k8–/–macrophages. Data is representative of
3 independent experiments.
(TIFF)
S1 Table. TPL-2 regulates lipolysis in M2 macrophages. Bone marrow-derived macrophages
(BMDM) were stimulated with IL-4 and IL-13 for 24 hours, as in Fig 4. Analysis of genes
involved in lipid metabolism was performed by Ingenuity pathways analysis. Gene expression
is indicated, relative to un-stimulated macrophages. Highlighted genes are either absent in
Map3k8–/–M2macrophages (Map3k8-dependent) or absent in both WT andMap3k8–/–M2
macrophages.
(PDF)
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